A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ? 1 to < 31 Years Old with First Relapse

Phase

Phase II Clinical Trial

Condition(s)

Leukemia

Trial Number

04546399

Trial Status

OPEN